Topic: management changes
The departure of BMS' Paul Biondi, who presided over an extensive deal-making strategy, adds to the challenges presented by the Celgene integration.
Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.
Sanofi CEO Paul Hudson hinted at a coming shakeup—from diabetes to cancer and R&D to marketing. And he's planning to unveil those plans December 10.
Pfizer executive chairman Ian Read, who handed off the CEO baton to Albert Bourla this year, will now step aside completely and retire at year's end.
Patient centricity may be a catchphrase, but with a new exec poached from Sanofi, Astellas is working to puts its money where its mouth is.
The former National Cancer Institute director reportedly has support from five ex-FDA commissioners, including his predecessor, Scott Gottlieb.
Salix Pharmaceuticals President Mark McKenna is leaving Bausch Health for a precision medicine company.
New CEO Paul Hudson is going on a barnstorming tour to meet Sanofi employees, but he knows he has far more to do than meet and greet.
Teva's CEO Kåre Schultz has had his hands full since taking the helm in 2017. Now, he needs to locate his next finance chief.
McCann Health taps Hilary Gentile for new role as its first global chief strategy office.